25 XP   0   0   10

Zhejiang CONBA Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Zhejiang CONBA Pharmaceutical Co Ltd together

PenkeI guess you are interested in Zhejiang CONBA Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zhejiang CONBA Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zhejiang CONBA Pharmaceutical Co Ltd

I send you an email if I find something interesting about Zhejiang CONBA Pharmaceutical Co Ltd.

Quick analysis of Zhejiang CONBA Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Zhejiang CONBA Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.11
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥2.85
Expected worth in 1 year
¥2.74
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
¥0.66
Return On Investment
13.4%

For what price can you sell your share?

Current Price per Share
¥4.91
Expected price per share
¥4.7 - ¥5.29
How sure are you?
50%

1. Valuation of Zhejiang CONBA Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥4.91

Intrinsic Value Per Share

¥2.36 - ¥3.70

Total Value Per Share

¥5.21 - ¥6.55

2. Growth of Zhejiang CONBA Pharmaceutical Co Ltd (5 min.)




Is Zhejiang CONBA Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$1b-$9.4m-0.9%

How much money is Zhejiang CONBA Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$49.4m$277.2m-$227.8m-461.1%
Net Profit Margin6.0%32.7%--

How much money comes from the company's main activities?

3. Financial Health of Zhejiang CONBA Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of Zhejiang CONBA Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Zhejiang CONBA Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Zhejiang CONBA Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Zhejiang CONBA Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Zhejiang CONBA Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zhejiang CONBA Pharmaceutical Co Ltd is ¥4.91. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zhejiang CONBA Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zhejiang CONBA Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥2.85. Based on the TTM, the Book Value Change Per Share is ¥-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.87 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.19 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zhejiang CONBA Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.020.4%0.020.4%0.112.2%0.040.7%0.030.6%
Usd Book Value Change Per Share0.00-0.1%0.00-0.1%0.122.4%0.020.3%0.030.5%
Usd Dividend Per Share0.030.5%0.030.5%0.000.1%0.020.4%0.020.3%
Usd Total Gains Per Share0.020.5%0.020.5%0.122.5%0.030.7%0.040.9%
Usd Price Per Share0.65-0.65-0.69-0.73-1.14-
Price to Earnings Ratio33.95-33.95-6.37-7.99-33.95-
Price-to-Total Gains Ratio28.79-28.79-5.53-16.38-34.64-
Price to Book Ratio1.66-1.66-1.74-2.36-5.15-
Price-to-Total Gains Ratio28.79-28.79-5.53-16.38-34.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.67758
Number of shares1475
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.02
Usd Book Value Change Per Share0.000.02
Usd Total Gains Per Share0.020.03
Gains per Quarter (1475 shares)33.4450.07
Gains per Year (1475 shares)133.76200.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1155-2212410694190
2311-43258213188390
3466-65392319281590
4621-86526426375790
5777-108660532469990
6932-1307946395631190
71087-1519287456571390
81243-17310628527501590
91398-19411969588441790
101553-216133010659381990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%21.01.00.095.5%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%6.04.00.060.0%17.05.00.077.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.02.090.9%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%20.02.00.090.9%

Fundamentals of Zhejiang CONBA Pharmaceutical Co Ltd

About Zhejiang CONBA Pharmaceutical Co Ltd

Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, manufacturing, and sales of medicines and general health products in China. It offers Chinese herbal decoction pieces, Chinese patent medicines, chemical pharmaceutical products, chemical raw materials, medical devices, and biological products. The company also provides pharmaceutical dosage forms, including tablets, capsules, pills, dripping pills, granules, powders, injections, freeze-dried powder injections, oral liquids, syrups, nasal drops, ointments, etc. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1993 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.

Fundamental data was last updated by Penke on 2024-04-17 08:47:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Zhejiang CONBA Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zhejiang CONBA Pharmaceutical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 6.0% means that ¥0.06 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 6.0%. The company is making a profit. +1
  • The TTM is 6.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.0%TTM6.0%0.0%
TTM6.0%YOY32.7%-26.7%
TTM6.0%5Y10.6%-4.6%
5Y10.6%10Y11.2%-0.6%
1.1.2. Return on Assets

Shows how efficient Zhejiang CONBA Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.3% Return on Assets means that Zhejiang CONBA Pharmaceutical Co Ltd generated ¥0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 3.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.3%TTM3.3%0.0%
TTM3.3%YOY18.6%-15.3%
TTM3.3%5Y6.2%-2.9%
5Y6.2%10Y6.6%-0.5%
1.1.3. Return on Equity

Shows how efficient Zhejiang CONBA Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 5.2% Return on Equity means Zhejiang CONBA Pharmaceutical Co Ltd generated ¥0.05 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 5.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.2%TTM5.2%0.0%
TTM5.2%YOY28.5%-23.3%
TTM5.2%5Y9.9%-4.7%
5Y9.9%10Y12.0%-2.1%

1.2. Operating Efficiency of Zhejiang CONBA Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zhejiang CONBA Pharmaceutical Co Ltd is operating .

  • Measures how much profit Zhejiang CONBA Pharmaceutical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 11.5% means the company generated ¥0.11  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 11.5%. The company is operating less efficient.
  • The TTM is 11.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.5%TTM11.5%0.0%
TTM11.5%YOY11.0%+0.5%
TTM11.5%5Y12.4%-0.9%
5Y12.4%10Y11.2%+1.2%
1.2.2. Operating Ratio

Measures how efficient Zhejiang CONBA Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.27 means that the operating costs are ¥1.27 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 1.275. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.275. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.275TTM1.2750.000
TTM1.275YOY1.214+0.060
TTM1.2755Y1.172+0.103
5Y1.17210Y1.019+0.153

1.3. Liquidity of Zhejiang CONBA Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zhejiang CONBA Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.93 means the company has ¥1.93 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 1.934. The company is able to pay all its short-term debts. +1
  • The TTM is 1.934. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.934TTM1.9340.000
TTM1.934YOY1.725+0.209
TTM1.9345Y1.479+0.455
5Y1.47910Y1.198+0.281
1.3.2. Quick Ratio

Measures if Zhejiang CONBA Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.34 means the company can pay off ¥0.34 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 0.342. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.342. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.342TTM0.3420.000
TTM0.342YOY0.302+0.040
TTM0.3425Y0.372-0.031
5Y0.37210Y0.469-0.096

1.4. Solvency of Zhejiang CONBA Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zhejiang CONBA Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.33 means that Zhejiang CONBA Pharmaceutical Co Ltd assets are financed with 33.0% credit (debt) and the remaining percentage (100% - 33.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 0.330. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.330. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.330TTM0.3300.000
TTM0.330YOY0.315+0.015
TTM0.3305Y0.405-0.075
5Y0.40510Y0.428-0.023
1.4.2. Debt to Equity Ratio

Measures if Zhejiang CONBA Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 52.2% means that company has ¥0.52 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The MRQ is 0.522. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.522. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.522TTM0.5220.000
TTM0.522YOY0.482+0.040
TTM0.5225Y0.742-0.221
5Y0.74210Y0.831-0.089

2. Market Valuation of Zhejiang CONBA Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Zhejiang CONBA Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Zhejiang CONBA Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 33.95 means the investor is paying ¥33.95 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The EOD is 35.238. Based on the earnings, the company is overpriced. -1
  • The MRQ is 33.947. Based on the earnings, the company is overpriced. -1
  • The TTM is 33.947. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD35.238MRQ33.947+1.292
MRQ33.947TTM33.9470.000
TTM33.947YOY6.369+27.577
TTM33.9475Y7.995+25.952
5Y7.99510Y33.949-25.955
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The EOD is 14.610. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 14.074. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 14.074. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD14.610MRQ14.074+0.536
MRQ14.074TTM14.0740.000
TTM14.074YOY39.962-25.888
TTM14.0745Y38.026-23.952
5Y38.02610Y38.387-0.360
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zhejiang CONBA Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Zhejiang CONBA Pharmaceutical Co Ltd:

  • The EOD is 1.723. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.660. Based on the equity, the company is underpriced. +1
  • The TTM is 1.660. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.723MRQ1.660+0.063
MRQ1.660TTM1.6600.000
TTM1.660YOY1.738-0.079
TTM1.6605Y2.359-0.699
5Y2.35910Y5.152-2.793
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Zhejiang CONBA Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.027-0.0270%0.871-103%0.115-123%0.190-114%
Book Value Per Share--2.8502.8500%2.876-1%2.351+21%1.987+43%
Current Ratio--1.9341.9340%1.725+12%1.479+31%1.198+61%
Debt To Asset Ratio--0.3300.3300%0.315+5%0.405-19%0.428-23%
Debt To Equity Ratio--0.5220.5220%0.482+8%0.742-30%0.831-37%
Dividend Per Share--0.1910.1910%0.033+477%0.131+46%0.119+60%
Eps--0.1390.1390%0.785-82%0.254-45%0.227-39%
Free Cash Flow Per Share--0.3360.3360%0.125+169%0.213+58%0.171+97%
Free Cash Flow To Equity Per Share--0.3360.3360%-0.274+182%0.025+1268%0.107+213%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.699--------
Intrinsic Value_10Y_min--2.364--------
Intrinsic Value_1Y_max--0.279--------
Intrinsic Value_1Y_min--0.189--------
Intrinsic Value_3Y_max--0.907--------
Intrinsic Value_3Y_min--0.613--------
Intrinsic Value_5Y_max--1.620--------
Intrinsic Value_5Y_min--1.083--------
Market Cap12618896714.240+4%12156289502.72012156289502.7200%12850200320.000-5%13958159196.144-13%21458659618.247-43%
Net Profit Margin--0.0600.0600%0.327-82%0.106-44%0.112-47%
Operating Margin--0.1150.1150%0.110+5%0.124-7%0.112+3%
Operating Ratio--1.2751.2750%1.214+5%1.172+9%1.019+25%
Pb Ratio1.723+4%1.6601.6600%1.738-5%2.359-30%5.152-68%
Pe Ratio35.238+4%33.94733.9470%6.369+433%7.995+325%33.9490%
Price Per Share4.910+4%4.7304.7300%5.000-5%5.304-11%8.286-43%
Price To Free Cash Flow Ratio14.610+4%14.07414.0740%39.962-65%38.026-63%38.387-63%
Price To Total Gains Ratio29.887+4%28.79228.7920%5.532+420%16.375+76%34.641-17%
Quick Ratio--0.3420.3420%0.302+13%0.372-8%0.469-27%
Return On Assets--0.0330.0330%0.186-82%0.062-47%0.066-51%
Return On Equity--0.0520.0520%0.285-82%0.099-48%0.120-57%
Total Gains Per Share--0.1640.1640%0.904-82%0.246-33%0.309-47%
Usd Book Value--1010715396.5511010715396.5510%1020117388.913-1%850104651.722+19%712906491.594+42%
Usd Book Value Change Per Share---0.004-0.0040%0.120-103%0.016-123%0.026-114%
Usd Book Value Per Share--0.3930.3930%0.397-1%0.324+21%0.274+43%
Usd Dividend Per Share--0.0260.0260%0.005+477%0.018+46%0.016+60%
Usd Eps--0.0190.0190%0.108-82%0.035-45%0.031-39%
Usd Free Cash Flow--119194794.754119194794.7540%44375581.304+169%77209708.181+54%61373036.768+94%
Usd Free Cash Flow Per Share--0.0460.0460%0.017+169%0.029+58%0.024+97%
Usd Free Cash Flow To Equity Per Share--0.0460.0460%-0.038+182%0.003+1268%0.015+213%
Usd Market Cap1741407746.565+4%1677567951.3751677567951.3750%1773327644.160-5%1926225969.068-13%2961295027.318-43%
Usd Price Per Share0.678+4%0.6530.6530%0.690-5%0.732-11%1.143-43%
Usd Profit--49417781.74449417781.7440%277273611.845-82%90494806.544-45%80606788.094-39%
Usd Revenue--828061188.335828061188.3350%848818760.513-2%872581154.198-5%754790395.341+10%
Usd Total Gains Per Share--0.0230.0230%0.125-82%0.034-33%0.043-47%
 EOD+4 -4MRQTTM+0 -0YOY+14 -215Y+17 -1810Y+19 -16

3.2. Fundamental Score

Let's check the fundamental score of Zhejiang CONBA Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1535.238
Price to Book Ratio (EOD)Between0-11.723
Net Profit Margin (MRQ)Greater than00.060
Operating Margin (MRQ)Greater than00.115
Quick Ratio (MRQ)Greater than10.342
Current Ratio (MRQ)Greater than11.934
Debt to Asset Ratio (MRQ)Less than10.330
Debt to Equity Ratio (MRQ)Less than10.522
Return on Equity (MRQ)Greater than0.150.052
Return on Assets (MRQ)Greater than0.050.033
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Zhejiang CONBA Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.273
Ma 20Greater thanMa 504.923
Ma 50Greater thanMa 1004.906
Ma 100Greater thanMa 2004.939
OpenGreater thanClose4.860
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Net Interest Income  -72,482-53,992-126,47423,685-102,78943,314-59,47564,4704,995



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets10,929,965
Total Liabilities3,605,940
Total Stockholder Equity6,913,851
 As reported
Total Liabilities 3,605,940
Total Stockholder Equity+ 6,913,851
Total Assets = 10,929,965

Assets

Total Assets10,929,965
Total Current Assets5,395,472
Long-term Assets5,534,493
Total Current Assets
Cash And Cash Equivalents 2,468,032
Net Receivables 953,307
Inventory 1,127,899
Other Current Assets 101,735
Total Current Assets  (as reported)5,395,472
Total Current Assets  (calculated)4,650,974
+/- 744,498
Long-term Assets
Property Plant Equipment 3,222,035
Goodwill 184,723
Intangible Assets 390,788
Other Assets 109,539
Long-term Assets  (as reported)5,534,493
Long-term Assets  (calculated)3,907,085
+/- 1,627,408

Liabilities & Shareholders' Equity

Total Current Liabilities2,789,113
Long-term Liabilities816,828
Total Stockholder Equity6,913,851
Total Current Liabilities
Short Long Term Debt 717,734
Accounts payable 514,184
Other Current Liabilities 407,702
Total Current Liabilities  (as reported)2,789,113
Total Current Liabilities  (calculated)1,639,620
+/- 1,149,493
Long-term Liabilities
Long term Debt 330,303
Capital Lease Obligations Min Short Term Debt3,970
Long-term Liabilities  (as reported)816,828
Long-term Liabilities  (calculated)334,273
+/- 482,555
Total Stockholder Equity
Retained Earnings 3,580,405
Total Stockholder Equity (as reported)6,913,851
Total Stockholder Equity (calculated)3,580,405
+/- 3,333,446
Other
Capital Stock2,570,037
Common Stock Shares Outstanding 2,570,037
Net Invested Capital 7,961,888
Net Tangible Assets 6,338,341
Net Working Capital 2,606,359
Property Plant and Equipment Gross 3,222,035



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-31
> Total Assets 
447,632
462,629
581,655
981,413
1,155,629
1,255,854
1,548,066
1,569,264
1,928,185
2,463,458
2,960,439
4,538,690
4,453,846
6,298,877
9,568,799
8,495,212
9,420,221
10,713,405
9,860,342
9,278,585
10,792,748
10,929,965
10,929,96510,792,7489,278,5859,860,34210,713,4059,420,2218,495,2129,568,7996,298,8774,453,8464,538,6902,960,4392,463,4581,928,1851,569,2641,548,0661,255,8541,155,629981,413581,655462,629447,632
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,969,596
3,833,961
4,661,840
4,852,967
4,797,595
4,137,515
5,465,801
5,395,472
5,395,4725,465,8014,137,5154,797,5954,852,9674,661,8403,833,9614,969,59600000000000000
       Cash And Cash Equivalents 
137,839
103,918
137,697
327,991
329,017
270,311
374,913
360,460
316,340
672,049
720,320
1,550,049
781,996
668,941
1,796,976
1,912,060
2,167,947
1,577,558
1,691,204
1,575,058
2,487,258
2,468,032
2,468,0322,487,2581,575,0581,691,2041,577,5582,167,9471,912,0601,796,976668,941781,9961,550,049720,320672,049316,340360,460374,913270,311329,017327,991137,697103,918137,839
       Short-term Investments 
1,221
270
174
168
172
240
936
64
0
0
0
0
0
5,500
200,000
71,477
144,019
54,872
13,044
1,795
0
0
001,79513,04454,872144,01971,477200,0005,50000000649362401721681742701,221
       Net Receivables 
91,314
61,966
60,171
131,629
175,399
231,752
286,516
277,918
415,394
488,188
590,751
685,239
861,022
857,752
1,756,909
1,123,761
1,372,985
1,913,762
1,738,922
859,992
955,219
953,307
953,307955,219859,9921,738,9221,913,7621,372,9851,123,7611,756,909857,752861,022685,239590,751488,188415,394277,918286,516231,752175,399131,62960,17161,96691,314
       Other Current Assets 
2,319
9,545
13,494
20,780
16,699
15,730
13,683
32,990
37,000
55,788
51,143
38,447
100,319
47,211
157,330
61,636
56,756
69,782
69,368
92,951
92,165
101,735
101,73592,16592,95169,36869,78256,75661,636157,33047,211100,31938,44751,14355,78837,00032,99013,68315,73016,69920,78013,4949,5452,319
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,661,251
4,758,381
5,959,230
5,062,747
5,141,070
5,681,586
5,534,493
5,534,4935,681,5865,141,0705,062,7475,959,2304,758,3814,661,251000000000000000
       Property Plant Equipment 
121,518
202,621
236,205
321,209
431,694
517,024
531,919
525,503
769,594
806,866
933,916
1,276,803
1,685,835
2,063,320
2,255,097
2,448,878
2,629,894
2,813,706
2,823,346
3,015,824
3,196,501
3,222,035
3,222,0353,196,5013,015,8242,823,3462,813,7062,629,8942,448,8782,255,0972,063,3201,685,8351,276,803933,916806,866769,594525,503531,919517,024431,694321,209236,205202,621121,518
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
920,802
1,078,755
913,099
913,099
913,099
225,600
172,608
151,587
184,723
184,723151,587172,608225,600913,099913,099913,0991,078,755920,8020000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
430,401
600,716
597,971
1,577,780
0
0
0
0
00001,577,780597,971600,716430,40100000000000000
       Intangible Assets 
16,239
14,662
12,319
64,258
65,194
56,424
23,029
21,110
19,091
21,790
25,014
57,471
57,110
1,420,455
589,582
481,907
464,984
467,736
398,508
377,824
362,035
390,788
390,788362,035377,824398,508467,736464,984481,907589,5821,420,45557,11057,47125,01421,79019,09121,11023,02956,42465,19464,25812,31914,66216,239
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38,203
22,812
35,227
25,273
36,675
21,251
8,891
8,89121,25136,67525,27335,22722,81238,203000000000000000
> Total Liabilities 
265,743
261,877
342,216
416,367
560,553
628,198
693,323
649,604
780,763
747,338
1,348,314
2,098,033
1,862,325
2,928,604
5,003,467
4,006,999
3,576,563
4,920,818
4,917,632
3,929,169
3,400,593
3,605,940
3,605,9403,400,5933,929,1694,917,6324,920,8183,576,5634,006,9995,003,4672,928,6041,862,3252,098,0331,348,314747,338780,763649,604693,323628,198560,553416,367342,216261,877265,743
   > Total Current Liabilities 
216,670
170,657
275,110
378,457
551,783
610,439
681,309
647,750
719,668
681,965
710,938
1,346,021
1,073,346
1,845,228
4,259,962
2,709,539
2,326,175
3,604,218
4,295,253
3,252,806
3,167,809
2,789,113
2,789,1133,167,8093,252,8064,295,2533,604,2182,326,1752,709,5394,259,9621,845,2281,073,3461,346,021710,938681,965719,668647,750681,309610,439551,783378,457275,110170,657216,670
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
794,107
856,800
486,000
1,280,900
0
0
0
0
00001,280,900486,000856,800794,10700000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
794,107
856,800
486,000
1,280,900
2,152,133
1,748,471
1,343,852
717,734
717,7341,343,8521,748,4712,152,1331,280,900486,000856,800794,10700000000000000
       Accounts payable 
34,205
34,763
55,845
76,367
114,620
112,883
115,323
118,620
131,339
141,667
143,643
178,611
248,538
190,136
885,667
198,384
271,513
300,273
299,122
270,967
540,191
514,184
514,184540,191270,967299,122300,273271,513198,384885,667190,136248,538178,611143,643141,667131,339118,620115,323112,883114,62076,36755,84534,76334,205
       Other Current Liabilities 
64,125
38,214
55,275
71,430
74,423
78,896
122,306
102,630
190,579
202,298
329,295
493,450
419,158
801,034
1,009,341
1,167,539
711,134
519,321
440,431
412,075
275,986
407,702
407,702275,986412,075440,431519,321711,1341,167,5391,009,341801,034419,158493,450329,295202,298190,579102,630122,30678,89674,42371,43055,27538,21464,125
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,297,460
1,250,388
1,378,840
622,379
676,363
461,020
816,828
816,828461,020676,363622,3791,378,8401,250,3881,297,460000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-794,107
-856,800
-486,000
-1,280,900
0
4,150
1,870
3,970
3,9701,8704,1500-1,280,900-486,000-856,800-794,10700000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,289
5,031
3,774
2,516
0
0
0
0002,5163,7745,0316,289000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,922
6,422
17,841
64,210
59,251
51,469
66,807
0
066,80751,46959,25164,21017,8416,4226,92200000000000000
> Total Stockholder Equity
178,298
197,201
237,567
517,980
534,168
562,603
846,110
911,157
997,302
1,538,967
1,420,766
2,174,513
2,367,615
2,790,426
4,141,476
4,304,618
5,728,929
5,649,943
4,662,379
5,026,171
7,060,821
6,913,851
6,913,8517,060,8215,026,1714,662,3795,649,9435,728,9294,304,6184,141,4762,790,4262,367,6152,174,5131,420,7661,538,967997,302911,157846,110562,603534,168517,980237,567197,201178,298
   Common Stock
97,200
97,200
97,200
137,200
137,200
137,200
180,000
324,000
324,000
351,800
703,600
809,600
809,600
809,600
1,673,820
2,510,730
2,667,320
2,667,320
2,667,320
2,667,320
2,570,037
0
02,570,0372,667,3202,667,3202,667,3202,667,3202,510,7301,673,820809,600809,600809,600703,600351,800324,000324,000180,000137,200137,200137,20097,20097,20097,200
   Retained Earnings 
34,757
44,485
76,718
42,349
50,137
78,840
181,255
204,549
261,943
386,742
533,277
550,237
857,186
1,407,070
1,483,139
1,725,693
2,135,522
2,544,413
1,813,280
2,266,582
4,270,767
3,580,405
3,580,4054,270,7672,266,5821,813,2802,544,4132,135,5221,725,6931,483,1391,407,070857,186550,237533,277386,742261,943204,549181,25578,84050,13742,34976,71844,48534,757
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
131
511
100
402
486
285
268
0
026828548640210051113100000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue6,696,442
Cost of Revenue-2,737,069
Gross Profit3,959,3733,959,373
 
Operating Income (+$)
Gross Profit3,959,373
Operating Expense-5,772,771
Operating Income923,671-1,813,398
 
Operating Expense (+$)
Research Development216,860
Selling General Administrative2,462,987
Selling And Marketing Expenses-
Operating Expense5,772,7712,679,847
 
Net Interest Income (+$)
Interest Income57,989
Interest Expense-41,313
Other Finance Cost-11,971
Net Interest Income4,705
 
Pretax Income (+$)
Operating Income923,671
Net Interest Income4,705
Other Non-Operating Income Expenses-
Income Before Tax (EBT)973,615923,671
EBIT - interestExpense = -41,313
752,006
793,319
Interest Expense41,313
Earnings Before Interest and Taxes (EBIT)-1,014,928
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax973,615
Tax Provision-117,348
Net Income From Continuing Ops856,267856,267
Net Income752,006
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--4,705
 

Technical Analysis of Zhejiang CONBA Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zhejiang CONBA Pharmaceutical Co Ltd. The general trend of Zhejiang CONBA Pharmaceutical Co Ltd is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zhejiang CONBA Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zhejiang CONBA Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.08 < 5.16 < 5.29.

The bearish price targets are: 4.74 > 4.7 > 4.7.

Tweet this
Zhejiang CONBA Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zhejiang CONBA Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zhejiang CONBA Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zhejiang CONBA Pharmaceutical Co Ltd. The current macd is 0.01050051.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zhejiang CONBA Pharmaceutical Co Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Zhejiang CONBA Pharmaceutical Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Zhejiang CONBA Pharmaceutical Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Zhejiang CONBA Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zhejiang CONBA Pharmaceutical Co Ltd. The current adx is 12.98.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Zhejiang CONBA Pharmaceutical Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Zhejiang CONBA Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zhejiang CONBA Pharmaceutical Co Ltd. The current sar is 5.13515781.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Zhejiang CONBA Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zhejiang CONBA Pharmaceutical Co Ltd. The current rsi is 49.27. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Zhejiang CONBA Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zhejiang CONBA Pharmaceutical Co Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zhejiang CONBA Pharmaceutical Co Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Zhejiang CONBA Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zhejiang CONBA Pharmaceutical Co Ltd. The current cci is -40.67714042.

Zhejiang CONBA Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zhejiang CONBA Pharmaceutical Co Ltd. The current cmo is -5.02969391.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Zhejiang CONBA Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zhejiang CONBA Pharmaceutical Co Ltd. The current willr is -78.125.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Zhejiang CONBA Pharmaceutical Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Zhejiang CONBA Pharmaceutical Co Ltd Daily Williams %R ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zhejiang CONBA Pharmaceutical Co Ltd.

Zhejiang CONBA Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zhejiang CONBA Pharmaceutical Co Ltd. The current atr is 0.1125018.

Zhejiang CONBA Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zhejiang CONBA Pharmaceutical Co Ltd. The current obv is 958,661,248.

Zhejiang CONBA Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zhejiang CONBA Pharmaceutical Co Ltd. The current mfi is 52.54.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Zhejiang CONBA Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartZhejiang CONBA Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zhejiang CONBA Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Zhejiang CONBA Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zhejiang CONBA Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.273
Ma 20Greater thanMa 504.923
Ma 50Greater thanMa 1004.906
Ma 100Greater thanMa 2004.939
OpenGreater thanClose4.860
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zhejiang CONBA Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Zhejiang CONBA Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zhejiang CONBA Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zhejiang CONBA Pharmaceutical Co Ltd

I send you an email if I find something interesting about Zhejiang CONBA Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Zhejiang CONBA Pharmaceutical Co Ltd.

Receive notifications about Zhejiang CONBA Pharmaceutical Co Ltd in your mailbox!